Search results for "position paper"

showing 10 items of 97 documents

Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: A European consensus position paper

2015

While they account for one-fifth of new cancer cases, rare cancers are difficult to study. A higher than average degree of uncertainty should be accommodated for clinical as well as for population-based decision making. Rules of rational decision making in conditions of uncertainty should be rigorously followed and would need widely informative clinical trials. In principle, any piece of new evidence would need to be exploited in rare cancers. Methodologies to explicitly weigh and combine all the available evidence should be refined, and the Bayesian logic can be instrumental to this end. Likewise, Bayesian-design trials may help optimize the low number of patients liable to be enrolled in …

Research designPathologyData baseResearch methodologyElectronic medical recordDiseaseReviewProceduresTreatment responseClinical trials; Rare cancers; Research methodology; Clinical Studies as Topic; Humans; Neoplasms; Rare Diseases; Research Design; Hematology; OncologyClinical trialsNeoplasmsReimbursementPriority journaleducation.field_of_studyClinical Studies as TopicClinical studies as topicHematologyRare diseasesEuropeOncologyResearch designResearch DesignClinical decision makingHumanmedicine.medical_specialtyPractice guidelineCase findingPopulationHealth care qualityReviewsCancer researchClinical studyRare DiseasesSDG 3 - Good Health and Well-beingConceptual frameworkmedicineHumansRare cancersTumor markerIntensive care medicineeducationAntineoplastic activityFlexibility (engineering)Surrogate endpointbusiness.industryMethodologyRare cancerStudy designCancer survivalReimbursementClinical trialClinical trials; Rare cancers; Research methodology; Hematology; OncologyPatient informationClinical effectivenessPosition paperNeoplasmbusinessRare disease
researchProduct

Position paper on nasal obstruction: evaluation and treatment.

2018

Nasal obstruction (NO) is defined as the subjective perception of discomfort or difficulty in the passage of air through the nostrils. It is a common reason for consultation in primary and specialized care and may affect up to 30%-40% of the population. It affects quality of life (especially sleep) and lowers work efficiency. The aim of this document is to agree on how to treat NO, establish a methodology for evaluating and diagnosing it, and define an individualized approach to its treatment. NO can be unilateral or bilateral, intermittent or persistent and may be caused by local or systemic factors, which may be anatomical, inflammatory, neurological, hormonal, functional, environmental, …

Rhinometry Acousticmedicine.medical_specialtyVisual analogue scaleImmunologyPopulationPhysical examination03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Acoustic rhinometrymedicineImmunology and AllergyAnimalsHumansMedical history030223 otorhinolaryngologyeducationIntensive care medicineeducation.field_of_studyObjective and subjective evaluationmedicine.diagnostic_testbusiness.industryNasal obstruction/nasal blockage/nasal respiratory insufficiencyMedical and surgical treatmentRhinomanometry030228 respiratory systemEtiologyQuality of LifePosition paperAcoustic rhinometryNasal CavityNasal ObstructionbusinessJournal of investigational allergologyclinical immunology
researchProduct

The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies

2021

The term liquid biopsy (LB) refers to the use of various biological fluids as a surrogate for neoplastic tissue to achieve information for diagnostic, prognostic and predictive purposes. In the current clinical practice, LB is used for the identification of driver mutations in circulating tumor DNA derived from both tumor tissue and circulating neoplastic cells. As suggested by a growing body of evidence, however, there are several clinical settings where biological samples other than tissue could be used in the routine practice to identify potentially predictive biomarkers of either response or resistance to targeted treatments. New applications are emerging as useful clinical tools, and o…

Societies ScientificCancer ResearchContext (language use)ReviewNeoplastic CellsBioinformaticsCirculating tumor cellCirculatingBiomarkers TumorMedicineHumansDigital polymerase chain reactionLiquid biopsycfDNAcirculating tumor DNAcfDNA; circulating cell-free DNA; circulating tumor DNA; ctDNA; digital PCR; liquid biopsy; next-generation sequencing; real-time PCRTumorCirculating Neoplastic Cellsliquid biopsybusiness.industrydigital PCRScientificctDNAcirculating cell-free DNANeoplastic Cells CirculatingCirculating Cell-Free DNAcfDNA; circulating cell-free DNA; circulating tumor DNA; ctDNA; digital PCR; liquid biopsy; next-generation sequencing; real-time PCR; Biomarkers Tumor; Humans; Italy; Liquid Biopsy; Neoplastic Cells Circulating; Societies ScientificOncologyItalyCirculating tumor DNAPosition papernext-generation sequencingSocietiesbusinessreal-time PCRBiomarkersHuman
researchProduct

The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societi…

2021

The personalized medicine is in a rapidly evolving scenario. The identification of actionable mutations is revolutionizing the therapeutic landscape of tumors. The morphological and histological tumor features are enriched by the extensive genomic profiling, and the first tumor-agnostic drugs have been approved regardless of tumor histology, guided by predictive and druggable genetic alterations. This new paradigm of "mutational oncology", presents a great potential to change the oncologic therapeutic scenario, but also some critical aspects need to be underlined. A process governance is mandatory to ensure the genomic testing accuracy and homogeneity, the economic sustainability, and the r…

Societies ScientificGenomic profilingDruggabilityNTRK-FusionsMedical OncologyNeoplasmsMedicineHumansAgnostic biomarkersPrecision MedicineHistology-agnosticTumor histologybusiness.industryAgnostic biomarkers; Agnostic drugs; Histology-agnostic; Homologous recombination deficiency; Microsatellite instability; Mismatch repair deficiency; NTRK-Fusions; Precision oncology; Humans; Italy; Medical Oncology; Precision Medicine; Neoplasms; Societies ScientificScientificPrecision oncologyHematologyPrecision medicineData scienceAgnostic drugsOncologyEconomic sustainabilityItalyAgnostic biomarkerMicrosatellite instabilityPosition paperNeoplasmIdentification (biology)Personalized medicineAgnostic drugNTRK-FusionbusinessSocietiesHomologous recombination deficiencyMismatch repair deficiencyHuman
researchProduct

Position paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the SISET, FCSA, SIBioC and SIPMeL

2018

Although direct oral anticoagulants (DOAC) do not require dose-adjustment on the basis of laboratory test results, the measurement of their anticoagulant effect is useful in special situations. This position paper issued by the Italian Scientific Societies that are mainly involved in the management of patients on DOAC is aimed at providing guidance to care-givers on which tests should be used and the situations in which testing is useful. The guidance is based on the data from the literature so far available and/or on consensus among experts.

Societies ScientificOralConsensusDOACAnticoagulantAnticoagulation; Consensus; DOAC; Thrombosis; Administration Oral; Anticoagulants; Drug Monitoring; Humans; Italy; Societies Scientific; Immunology and Allergy; HematologyAdministration OralAnticoagulantsConsensuThrombosisScientificHematologyLong-Term CareAnticoagulationSettore BIO/12 - Biochimica Clinica E Biologia Molecolare ClinicaItalyThrombosiAdministrationHumansImmunology and AllergyPosition PaperDOAC; anticoagulation; thrombosis; consensusDrug MonitoringSocietiesHuman
researchProduct

Position paper on the management of patients with obstructive sleep apnea and hypertension: joint recommendations by the European Society of Hyperten…

2012

This article is aimed at addressing the current state of the art in epidemiology, pathophysiology, diagnostic procedures and treatment options for appropriate management of obstructive sleep apnea (OSA) in cardiovascular (particularly hypertensive) patients, as well as for the management of cardiovascular diseases (particularly arterial hypertension) in OSA patients. The present document is the result of the work done by a panel of experts participating in the European Union COST (COoperation in Scientific and Technological research) ACTION B26 on OSA, with the endorsement of the European Respiratory Society (ERS) and the European Society of Hypertension (ESH). These recommendations are par…

Societies Scientificmedicine.medical_specialtyPhysiologyArterial hypertension continuous positive airway pressure treatment guidelines hypertension treatment obstructive sleep apnoeaComorbiditySettore MED/10 - Malattie Dell'Apparato RespiratorioCheyne–Stokes respirationEpidemiologyarterial hypertension continuous positive airway pressure treatment guidelines hypertension treatment obstructive sleep apneaInternal MedicinemedicineHumansmedia_common.cataloged_instanceEuropean unionIntensive care medicinemedia_commonSleep Apnea Obstructivebusiness.industrySleep apneaMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareComorbidityEuropeSurvival RateObstructive sleep apneaBlood pressureHypertensionPractice Guidelines as TopicPosition papermedicine.symptomCardiology and Cardiovascular Medicinebusiness
researchProduct

The Role of Nutraceuticals in Statin Intolerant Patients.

2018

Abstract Statins are the most common drugs administered for patients with cardiovascular disease. However, due to statin-associated muscle symptoms, adherence to statin therapy is challenging in clinical practice. Certain nutraceuticals, such as red yeast rice, bergamot, berberine, artichoke, soluble fiber, and plant sterols and stanols alone or in combination with each other, as well as with ezetimibe, might be considered as an alternative or add-on therapy to statins, although there is still insufficient evidence available with respect to long-term safety and effectiveness on cardiovascular disease prevention and treatment. These nutraceuticals could exert significant lipid-lowering activ…

Statinmedicine.drug_classDiseasecardiovascular risk ; dyslipidemia ; nutraceuticals ; position paper ; statin intolerance030204 cardiovascular system & hematologyBioinformaticsKlinikai orvostudományok03 medical and health sciences0302 clinical medicineNutraceuticalEzetimibeStatin intoleranceRed yeast riceMedicineHumansPosition paper030212 general & internal medicineEndothelial dysfunctionDyslipidemiasbusiness.industryClinical Studies as TopicOrvostudományokmedicine.diseaseCardiovascular risk3. Good healthDyslipidemiaDietary SupplementsArterial stiffnesslipids (amino acids peptides and proteins)nutraceuticalHydroxymethylglutaryl-CoA Reductase InhibitorNutraceuticalsHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessDyslipidemiaposition papermedicine.drugstatin intoleranceHuman
researchProduct

How to manage patients with polyvascular atherosclerotic disease. Position paper of the International Union of Angiology

2020

Atherosclerosis is a systemic disease affecting multiple arterial territories. Patients with clinical atherosclerotic disease in one vascular bed are likely to have asymptomatic or symptomatic atherosclerotic lesions in other vascular beds. Specifically, peripheral arterial disease (PAD) often coexists with coronary and carotid disease. With progression of atherosclerotic disease in one vascular bed, the risk of clinical manifestations in other territories increases and the incidence of adverse cardiovascular events increases substantially with the number of affected vascular beds. Classical risk factors are associated with the development of polyvascular atherosclerotic disease (PVD) in di…

Systemic diseasemedicine.medical_specialtymedicine.medical_treatmentCardiologyDisease030204 cardiovascular system & hematology030230 surgeryRevascularizationAsymptomaticPeripheral Arterial Disease03 medical and health sciences0302 clinical medicineRisk FactorsmedicineHumansIntensive care medicineAngiologybusiness.industryIncidence (epidemiology)GuidelineAtherosclerosismedicine.diseasePosition papermedicine.symptomCardiology and Cardiovascular MedicinebusinessInternational Angiology
researchProduct

Position paper - progress towards standards in integrated (aerobic) MBR modelling.

2020

Membrane bioreactor (MBR) models are useful tools for both design and management. The system complexity is high due to the involved number of processes which can be clustered in biological and physical ones. Literature studies are present and need to be harmonized in order to gain insights from the different studies and allow system optimization by applying a control. This position paper aims at defining the current state of the art of the main integrated MBR models reported in the literature. On the basis of a modelling review, a standardized terminology is proposed to facilitate the further development and comparison of integrated membrane fouling models for aerobic MBRs. ispartof: WATER …

TechnologyEnvironmental EngineeringComputer sciencePROCESS SIMULATIONPRESSURE SET-POINTReactors de membranaEnvironmental Sciences & Ecology02 engineering and technology010501 environmental sciencesMembrane bioreactorMembranes (Technology)01 natural sciencesSUBMERGED MEMBRANE BIOREACTOREngineeringBioreactorsMembrane reactorsCONTROL-SYSTEMterminology[SPI.GPROC]Engineering Sciences [physics]/Chemical and Process EngineeringDEPOSITIONOPTIMIZATION0105 earth and related environmental sciencesWater Science and TechnologyScience & TechnologyCAKE LAYER FORMATIONSettore ICAR/03 - Ingegneria Sanitaria-AmbientaleCOMPUTATIONAL FLUID-DYNAMICSMBR modellingMembrane foulingIntegrated modelMembranes (Tecnologia)Engineering EnvironmentalSystem optimizationMembranes ArtificialModels Theoretical021001 nanoscience & nanotechnologyTerminology6. Clean waterStandardized terminologyPhysical SciencesFILTRATIONWater ResourcesPosition paperBiochemical engineeringintegrated modelSENSITIVITY0210 nano-technologyLife Sciences & BiomedicineEnvironmental SciencesWater science and technology : a journal of the International Association on Water Pollution Research
researchProduct

Artificial Intelligence + Distributed Systems = Agents

2009

The connection with Wirth’s book goes beyond the title, albeit confining the area to modern Artificial Intelligence (AI). Whereas thirty years ago, to devise effective programs, it became necessary to enhance the classical algorithmic framework with approaches applied to limited and focused subdomains, in the context of broad-band technology and semantic web, applications - running in open, heterogeneous, dynamic and uncertain environments-current paradigms are not enough, because of the shift from programs to processes. Beside the structure as position paper, to give more weight to some basic assertions, results of recent research are abridged and commented upon in line with new paradigms.…

Theoretical computer scienceSpeedupComputer Networks and CommunicationsComputer sciencebusiness.industryDesign elements and principlesBounded rationalityComputer Science ApplicationsSoftwareComputational Theory and MathematicsPosition paperArtificial intelligencebusinessSemantic WebMerge (version control)International Journal of Computers Communications & Control
researchProduct